REG - Physiomics PLC - Senior Management Update

PhysiomicsAnnouncement

04/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230904:nRSD2013La&default-theme=true

RNS Number : 2013L  Physiomics PLC  04 September 2023

4 September 2023

 

Physiomics plc

("Physiomics" or "the Company")

 

Senior Management Update

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions, is pleased to announce the hiring of a new member of its
senior management team.  Effective today, Dr Peter Sargent will be joining
the Company as Chief Operating Officer ("COO").

Prior to joining us, Dr Sargent held a senior management role at global
consultancy business Syneos Health Inc (NASDAQ: SYNH), leading large teams of
professionals and servicing a variety of clients in the biopharmaceuticals
space.  Among his earlier roles, Dr Sargent has also been Head of Business
Development for the UK's National Institute for Health and Care Research
(NIHR), leading a team supporting global life science businesses access to
funding and research infrastructure in the UK.

The COO role will help to formulate the Company's overall business strategy
and play a pivotal role in driving its execution.  The initial focus will be
to strengthen the operational performance of the Company and in particular
drive the key priorities announced during the Company's recent placing,
namely:

·    further expansion and diversification of its client base;

·    expansion of its consulting business into the adjacent area of
pharmaceutical biostatistics services; and

·    exploration of opportunities around its personalised oncology
software offering.

 

Dr Sargent will join as a key member of the Company's senior leadership team
(but not as a board director) and will report directly to Dr Jim Millen.  The
hiring of Dr Sargent forms part of a strategy to revert to a more traditional
board structure where the roles of Executive Chairman and CEO are separated.

 

Executive Chairman & CEO, Dr Jim Millen, commented:

"I am delighted that Physiomics has been able to attract a candidate of the
calibre of Dr Peter Sargent, who joins us with significant experience of
building service businesses in the biopharmaceutical sector.  Peter will work
closely with myself and my senior management team to set and drive forwards
the Company's key business priorities and I look forward to him making a
significant positive impact."

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

This announcement is released by Physiomics plc and contains inside
information for the purposes of Article 7 of the Market Abuse Regulation (EU)
596/2014 (MAR), and is disclosed in accordance with the Company's obligations
under Article 17 of MAR.

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 100 projects, involving over 50 targets and 75 drugs, and
has worked with clients such as Merck KGaA, Astellas, Merck & Co and
Bicycle Therapeutics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPUUUBUPWPGW